Guggenheim has revised its price target for Eli Lilly (LLY, Financial), reducing it from $973 to $928 while maintaining a Buy rating on the stock. This adjustment comes as the firm updates its projections in anticipation of Eli Lilly's first-quarter earnings report scheduled for May 1.
One of the primary focuses for Guggenheim is the performance of Eli Lilly's tirzepatide franchise, which continues to play a significant role in the company's growth outlook. Current prescription trends indicate that both Guggenheim's and market consensus expectations for 2025 are well within reach, suggesting a solid performance trajectory for the company.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for Eli Lilly and Co (LLY, Financial) is $1,016.77 with a high estimate of $1,190.00 and a low estimate of $800.00. The average target implies an upside of 38.83% from the current price of $732.41. More detailed estimate data can be found on the Eli Lilly and Co (LLY) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, Eli Lilly and Co's (LLY, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Eli Lilly and Co (LLY, Financial) in one year is $1126.33, suggesting a upside of 53.78% from the current price of $732.41. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Eli Lilly and Co (LLY) Summary page.
